This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Q2 FY27 revenue rises 24.3%, profit after tax rises 29.3% year on year
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27, for the quarter ended September 30, 2026, revenue rose 24.3% year on year to INR 28,205 million; profit after tax rose 29.3% year on year to INR 3,251 million. EBITDA increased 30.9% to INR 5,748 million, with margin up from 19.3% to 20.4%. Consolidated H1 FY27 revenue was INR 54,009 million, profit after tax INR 6,176 million and operating cash flow INR 6,822 million.
Strong revenue, profit, margin and operating cash flow growth supports earnings momentum and may lift shareholder sentiment.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹2,820 Cr | ₹2,270 Cr | +24.3% |
| Operating profit | ₹442.6 Cr | ₹338.3 Cr | +30.8% |
| Profit after tax | ₹325.1 Cr | ₹251.4 Cr | +29.3% |
| EBITDA margin | 20.8% | 20.9% | −0.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.